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Introduction
Multiple cardiovascular risk factors (MCRFs) in cardiovascular diseases, such as chronically increased blood pressure, hyperlipidemia, hyperuricemia, hyperglycemia, and obesity, have a negative impact on the heart exposed to ischemia [1, 2] . It has been postulated that hematopoietic-derived progenitor cells have an effect on angiogenesis and tissue repair following several injuries, such as ischemia, reperfusion, inflammation, allograft vasculopathy, atherosclerosis, stroke, etc. [3] [4] [5] [6] . Many studies have demonstrated the presence of circulating endothelial progenitor cells (EPCs) in the peripheral circulation [5, 7] . Circulating EPCs have been defined previously using two distinct methods to characterize them, i.e., flow cytometry and cell culture; recently, however, the validity of both definitions has been questioned. Flow cytometric definition is based on the expression of CD34 + on the circulating cells. Usually, the recent studies using flow cytometry have investigated cells that express CD34 ). An alternative definition of EPCs describes colonies of spindle-shaped cells appearing after culture of blood-derived mononuclear cells. Сirculating EPCs, however, might not only have bone-marrow origin; they are also transformed from peripheral mononuclear cells that have the capacity to come to the sites of tissue injury and may be differentiated into mature endothelial cells [8, 9] . It has been determined that EPCs have been largely characterized by the expression of the primitive hematopoietic progenitor markers CD34 + and VEGF receptor (VEGFR)-2 [10, 11] . Basically, CD34 + CD45 − cells have nonhematopoietic origin; and recently they have been identified as putative EPCs by virtue of their ability to form "late outgrowth" colonies phenotypically and functionally indistinguishable from mature endothelial cell colonies in culture [12, 13] . Previous studies have shown an increase in the circulating concentration of population CD34 + CD45 − cells in patients with established coronary artery disease (CAD) and peripheral artery disease [10, 14, 15] , are not related to severity of CAD or clinical outcome in the patients with acute coronary syndrome and unstable angina. On the other hand, the concentrations of proangiogenic monocites may reflect the extent of vascular injury and atheroma burden in this patient population [3, 9] . The objective of this study was to evaluate the correlation between MCRF and various types of circulating mononuclear cells (CMCs) that express CD14 in patients with asymptomatic coronary artery disease.
Design and Methods

Study Population
The study population was structured retrospectively after determining the coronary artery disease (CAD) by contrast-enhanced spiral computed tomography angiography in 126 asymptomatic subjects.
Twenty five healthy volunteers were enrolled in the study aimed at the verification of the reference average of biological markers. All the subjects gave their written informed consent to participate in the study prior to enrollment. The following are the exclusion criteria: Symptomatic chronic heart failure; left ventricular ejection fraction (LVEF) ≤40%; uncontrolled diabetes mellitus; severe kidney and liver diseases that may affect clinical outcomes; malignancy; unstable angina; Q-wave and non-Q-wave MI within 30 days before the study entry; creatinin plasma level above 440 μmol/L; eGFR index <35 mL/min/m 2 ; brain injury within three months before the enrollment; body mass index above 30 kg/m 2 and less than 15 kg/m 2 ; pulmonary edema; tachyarrhythmia; valvular heart disease; thyrotoxicosis; ischemic stroke; intracranial hemorrhage; acute infections; surgery; trauma; all ischemic events within the three previous months; inflammations within the previous month; neoplasm; pregnancy; implanted pacemaker, any disorder that may discontinue the patient's participation in the study according to investigators; and finally the patient's refusal to participate in the study or to give his consent for it.
Contrast-Enhanced Spiral Computed Tomography Angiography
The coronary vessel-wall, plaque geometry, and compositional parameters were measured on contrast-enhanced spiral computed tomography (CT) angiography [16] . Contrast-enhanced spiral CT was performed on a Somatom Volum Zoom scanner (Siemens, Erlangen, Germany) with two rows of detectors (32 × 2 CT system) at the time of end-expiratory breath-hold. After noncontrast localization image acquisition, injection of Omnipak nonionic contrast (Amersham Health, Carrigtohill, Ireland) was used to determine the optimal coronary arterial image. Images were reconstructed in 0.6-mm axial slices. The coronary artery calcification was quantified by calculating the Agatston score index and measuring the calcification mass [17] . Calcified atherosclerotic plaque (CAP), high-density noncalcified plaque (HD-NCP), and low-density noncalcified plaque (LD-NCP) were determined. Calcified atherosclerotic plaques were characterized by an attenuation value that was 150 HU (Hounsfield units) or greater for CAP, 30 to 149 HU for HD-NCP U, and 100 to +30 HU for LD-NCP [18, 19] .
Echocardiography Examination
According to recommendation of the American Society of Echocardiography, standard transthoracic echocardiography in B-mode was performed on an ACUSON scanner (Siemens, Erlangen, Germany) using a transducer with a frequency of 2.5-5 MHz. End-diastolic and end-systolic LV volumes were obtained using a two-dimensional reference sector according to Simpson's method, and the LV ejection fraction (LVEF) was calculated according to conventional methods [20] .
Glomerular Filtration Ratio Estimation
Estimated glomerular filtration ratio (eGFR) was calculated using the MDRD formula [21] .
Blood Sampling and Biomarker Measurements
All the samples were placed into EDTA tubes with serum gel for further flow cytometry analysis and mononuclear cell preparation. The whole blood was analyzed: The complete blood count with white blood cell differential count was carried out using the analyzer. After taking for blood chemistry test, all the blood samples were placed in the cooling Vacutainer and centrifugated immediately (at a temperature of 4 °C at 6000 rpm for 15 min). After centrifugation, the serum was coded and stored in the refrigerator at a temperature of −70 °C until used.
High-Sensitive C-Reactive Protein Level Determination
High-sensitive C-RP (hs-C-RP) level was measured by a nephelometric technique and obtained with a "AU640 Analyzer" (Olympus Diagnostic Systems Group, Shizuoka-ken, Japan).
Serum Uric Acid Measurement
Serum uric acid level (SUA) was determined by enzymatic methods using a Beckman Synchron LX20 chemistry analyzer. The analytical average range for SUA was 0.5-12 mg/dL.
Cholesterol Level Measurement
Concentrations of total cholesterol (TC) and high density lipoprotein (HDL) cholesterol were determined with the Dimension Clinical Chemistry System (Dade Behring Inc., Newark, NJ, USA). Low density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula [22] .
Circulating EPCs
The flow cytometric technique (FCT) was used for predictably distinguishing circulating cell subsets, which depend on expression of CD45, CD34, CD14, Tie-2, and VEGFR2, using High-Definition Fluorescence Activated Cell Sorter (HD-FACS) methodology [23] . Accordingly, the cells in question were phenotyped on the basis of their forward scatter characteristic (FSC) and side scatter characteristic (SSC) profiles. The cells were directly stained and analyzed for phenotypic expression of surface proteins using anti-human monoclonal antibodies, including anti-CD45 FITS (BD Biosciences, San Jose, CA, USA), anti-CD34 FITS (BD Biosciences), anti-VEGFR-2 known as anti-CD309 (BD Biosciences), anti-Tie2 (BD Biosciences) and anti-CD14 (BD Biosciences). The fluorescence minus one technique was used to provide negative controls and establish positive stain boundaries. After lysis of erythrocytes with UTILIZE wash solution, the samples were centrifuged at 200× g for 15 min; then they were washed twice with PBS and fixed immediately. Double-or triple-positive events were determined using Boolean principles ("and", "not", "or", etc.). Circulating EPCs were defined as CD34/VEGFR2 positive cells with lack of CD45 expression. From each tube 500,000 events were analyzed. For CD14 
Cardiovascular Risk Calculation
A 10-year cardiovascular risk for study patients was calculated using the Framingham General Cardiovascular Risk Score (2008) by on-line calculator.
Statistical Analysis
All the statistical analyses were performed in SPSS for Windows v. 20.0 (SPSS Inc., Chicago, IL, USA, 2011). Continuous variables are presented as mean ± SD, mean and 95% CI or median and interquartile range. Categorical variables are expressed as frequencies and percentage. An independent group t-test was used to compare all the interval parameters matching the criteria of normality and homogeneity of variance. For interval parameters that fail to match these criteria, the non-paramentric Mann-Whitney test was used to compare variables. Categorical variables and frequencies were compared using Chi 2 test and Fisher exact test of independence. SUA frequencies were normally distributed (using the Kolmogorov-Smirnov test), and data were not positively skewed. Frequencies of CMCs and hs-CRP concentrations were not distributed. The data, however, were not transformed. The potential factors that may be associated with CMCs were identified first with the univariate analysis (ANOVA), and then the independent predictors of a decrease in CMCs were searched with the multivariate one-step backward logistic regression analysis, initially including variables for which a p value < 0.1 was achieved from the univariate analysis. The odds ratio (RR) and confidence intervals (95% CI) were calculated for factors independently associated with a decrease in circulating CMCs. A calculated difference of p < 0.05 was considered significant.
Results and Discussion
General characteristics of study patients are presented in Table 1 . Two groups of persons surveyed (healthy volunteers and patients with known CAD) were compared in terms of demographics, smoking, body mass index, CAD family history, mean systolic BP, heart rate, creatinin, fasting glucose and eGFR. Patients with known CAD, however, had hyperlipidaemia (44.4%), arterial hypertension (66.7%), T2DM (36.5%). An increase in HbA1c, serum uric acid, hs-CRP, LDL cholesterol, and triglycerides, as well as a decrease in HDL cholesterol were found in patients with known CAD when compared with healthy volunteers. Mediana of a 10-year Framingham General Cardiovascular Risk in patients with known CAD and in healthy volunteers was 23% and 2% respectively.
Baseline angiographic and treatment characteristics of patients with known CAD are presented in Table 2 . Calcified atherosclerotic plaques were determined in 96% of patients; HD-NCP and LD-NCP were found in 31% and 25% respectively. The median of the Agatston score index was 586 (95% CI = 401-838). Coronary arteries with plaques were determined in 36.5%; 33.3%; and 20.2% for one vessel, two vessels, three and more vessels respectively. Note: CAD-coronary artery disease, CI-confidence interval, T2DM-type 2 diabetes mellitus, eGFR-estimated glomerulal filtration ratio, TC-total cholesterol, HbA1c-glycated hemoglobin, LDL-low-density cholesterol, HDL-high-density cholesterol, SUA-serum uric acid, BP-blood pressure, hs-CRP-high sensitive C-reactive protein, LV EF-left ventricular ejection fraction.
All the asymptomatic patients were informed about coronary angiography, and they were treated according to current clinical guidelines with diet, lifestyle modification, and drug therapy that included ACE inhibitors/ARBs, aspirin or other antiagregants, statins and metformin if needed.
Analysis of the outcomes obtained showed no significant increase in circulating CD34+ subset cells (CD45 The odds ratio (OR) and confidence intervals (95% CI) were calculated for factors independently associated with CMC lowering (Table 4) . was performed. Analysis of the data obtained revealed that subjects with T2DM and calcification of coronary arteries determined with Agatston score index had a 1.16-fold and 1.14-fold increase in OR of CD14 Recent studies show that bone marrow-derived endothelial progenitor cells (EPCs) play an important role in the maintenance of endothelial integrity and atherosclerosis [3, 14] . A correlation between MCRF and concentration of CD34 [24] . Nevertheless, as the number of the existing cardiovascular risk factors varies among patients, simple CMC counts do not describe adequately a vascular disease risk in any clinical condition and, therefore, the CVD risk remains [24, 25] . The authors agree with Padfield G. J. et al. [15] cells when compared with isolated cardiovascular risk factors, even those such as T2DM and hs-CRP elevation in asymptomatic patients with known CAD. These findings may support a hypothesis of the impact of MCRFs on disorders of cellular protective mechanisms in subjects at an early stage of CAD.
Conclusion
The authors postulate that a reduction in circulating CD14 EPCs is related to a number of cardiovascular risk factors in asymptomatic patients with known CAD.
Study Restrictions
This study has some restrictions. The authors believe that a greater cohort is desirable to improve the power of the study. There is a variation in the definition of EPCs, the number of existing cardiovascular risk factors in various patients, and in the interaction between EPCs and other hematopoietic progenitor, inflammatory cells or platelets. The authors suppose that these restrictions might have no significant impact on the study data interpretation.
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